Study Results Show Smoking Cessation Timing Significantly Improves NSCLC Surgery Outcomes

Web Exclusives —March 28, 2022

Categories:

Lung Cancer

Lung cancer is the second most common cancer in the United States and is the leading cause of cancer mortality, accounting for 25% of all cancer deaths.1 The most common type of lung cancer is non–small-cell lung cancer (NSCLC), comprising 85% of all lung cancer cases.1 Early cases of NSCLC are treated with surgery that may have a curative effect.2 People who smoke have a much higher risk of developing lung cancer than nonsmokers, with smoking contributing to approximately 85% of NSCLC cases.1 In addition to being a risk factor for developing NSCLC, smoking also contributes to other adverse long-term outcomes, including the development of other primary cancers, all-cause mortality, and postoperative adverse events. As smoking is a modifiable risk factor, all patients with lung cancer are advised to quit smoking immediately through behavioral modifications and pharmacotherapy.

Preoperative smoking cessation is associated with fewer complications, but the available studies present conflicting evidence on how long of an interval between smoking cessation and surgery is ideal. To determine the association between duration of preoperative smoking cessation and short-term (30-day) postoperative complications and mortality, a retrospective cohort study of 9509 adult patients with clinical stage I NSCLC who underwent surgery between 2006 and 2016 at the Veterans Health Administration was performed. Patients aged <18 years, those who had never smoked, those having surgery for recurrent disease, and those who received neoadjuvant chemotherapy were excluded from the study.

Major complications were defined as stroke, pneumonia, renal failure, empyema, myocardial infarction, or respiratory failure. The study included 6168 patients who were smokers at the time of their diagnosis and 662 of these patients stopped smoking prior to surgery. Current smokers were generally younger, had a lower body mass index, and were more likely to experience a ≥12-week delay between diagnosis and surgery than former smokers. Current smokers were also more likely to have higher-grade tumors than former smokers. Pharmacotherapy for smoking cessation was offered to 1351 of the current smokers between diagnosis and surgery. Preoperative interventions that were associated with smoking cessation included prescribing smoking cessation pharmacotherapy, more frequent medical encounters, and an appointment with a primary care provider. Delaying surgery and the number of packs smoked per year had no association with smoking cessation likelihood.

Evaluation of the relationship between smoking cessation duration and the 30-day outcome of major complication or mortality revealed that there was a higher risk for complications or mortality associated with a higher Charlson comorbidity score and larger tumor size and a lower risk with a longer duration between smoking cessation and surgery and with a video-assisted thoracoscopic surgery approach. Those patients who ceased smoking ≥3 weeks prior to surgery had similar complication odds as nonsmokers (95% confidence interval, 0.702-1.437; P = .98). Those patients who continued to smoke had a shorter overall 5-year survival rate (56.1%) compared with a 61.7% survival rate among those patients who ceased smoking. The odds of major complications or mortality had a decrease of 8.1% for each week of successful smoking cessation prior to surgery.

Source

Heiden BT, Eaton DB Jr, Chang SH, et al. Assessment of duration of smoking cessation prior to surgical treatment of non-small cell lung cancer [published online ahead of print, November 18, 2021]. Ann Surg. 2021;10.1097/SLA.0000000000005312.

References

  1. American Cancer Society. Lung cancer statistics: how common is lung cancer? www.cancer.org/cancer/lung-cancer/about/key-statistics.html. Accessed February 22, 2022.
  2. American Cancer Society. Surgery for non-small cell lung cancer. www.cancer.org/cancer/lung-cancer/treating-non-small-cell/surgery.html. Accessed February 22, 2022.
Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country